Author/Authors :
Shahid Sales Soodabeh نويسنده Department of Radiation Oncology, Mashhad University of Medical Sciences, Mashhad , Ebrahimi Safieh نويسنده School of Medicine,Department of Medical Biochemistry,Mashhad University of Medical Sciences,Mashhad,Iran , Moradi Ali نويسنده Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , Ghasemi Faezeh نويسنده Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , Anvari Kazem نويسنده Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , Ahmadi Simab Saeideh نويسنده Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , Hassanian Seyed Mahdi نويسنده Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , Boroushaki Mohammad Taher نويسنده Department of Pharmacology and Pharmacological Research Center of Medicinal Plants, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , Avan Amir نويسنده Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract :
Introduction: Esophageal squamous cell carcinoma is among the leading causes
of cancer related deaths within gastrointestinal tumors. There is a growing body of
evidence that shows an association between Epstein Barr virus infection and the
development of malignancies such as B-cell non-Hodgkin’s lymphoma, Hodgkin’s
disease, and Burkett’s lymphoma. However its potential association with esophageal
squamous cell carcinoma is controversial. Therefore, in the present study, we have
explored the association of Epstein Barr virus with pathological information and
clinical outcomes of 108 esophageal squamous cell carcinoma patients.
Methods: There were 48% female and 52% male patients with a mean age of
59.2±11.1 years who enrolled in this study. Patients had the following tumor stages:
T1 (5.6%), T2 (21.3%), and T3 (71.3%). A total of 32.4% had lymph node metastases.
In order to explore whether patient characteristics might influence clinical outcome,
we analyzed data on progression-free survival and overall survival according to
patients’ clinicopathologic features.
Results:An association existed between tumor size, node and metastasis status, and
stage with shorter overall and progression-free survival. We observed that 6.5% of patients
had Epstein Barr virus. All patients infected with Epstein Barr virus had T2 and T3
disease.
Conclusion: Our findings demonstrated the presence of Epstein Barr virus in
6.5% of Iranian patients and its potential link with tumor size. Additional studies in multicenter
settings should be conducted to determine the association of Epstein Barr virus
with development and progression of esophageal squamous cell carcinoma.
